• Cullinan Therapeutics published an Immunology Day presentation centered on its T-cell engager portfolio across immunology and oncology.
• CLN-978 (CD19xCD3) Phase 1/2a: 42 patients treated across OUTRACE studies as of May 29, 2026.
• SLE efficacy: 10 of 14 patients with at least 4 weeks follow-up had a ≥4-point hSLEDAI reduction; 5 reached DORIS remission.
• Safety in 32 SLE or RA patients: CRS in 13 patients; 1 Grade 3 CRS at 45 micrograms led to stopping enrollment in that cohort.
• Strategy update flagged next steps for CLN-978; presentation also outlined initial data plans for BCMAxCD3 program velinotamig.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.